The bright future of Alzheimer’s disease pharmacotherapy

Alzheimer's disease (AD) is the most common cause of progressive dementia in the elderly population leading to progressive disturbances of cognitive functions. It is the disease whose prevalence is rising but with very limited numbers of drugs limiting its progression making more difficult to overcome the evil side of this disease. Currently, there are a number of drugs in pipeline blooming the hope to effectively modify the progression of AD. All of these newer agents are directing toward the biochemical mechanism of AD development including targeting tau protein (e.g. Inhibition of taukinase), targeting Aβ (e.g. β-Secretase Inhibitors), and therapies involving gene as well as stem cell strategies. Hence in this review, we summarized the pathogenesis of AD on which the discovery of these newer agents based in addition to giving a clear picture on these agents. [Int J Basic Clin Pharmacol 2014; 3(1.000): 10-17]